Aducanumab Seen As Potential AD 'Time Bomb' For Health Budgets
Alzheimer's disease is a common and growing global menace that threatens health care budgets, but if a cure was ever found demand for the remedy it would likely swamp payer resources.
You may also be interested in...
Biogen's chief medical officer says iPhone technology should in future be used for early warning diagnosis of Alzheimer's Disease.
Biogen Inc. has earmarked $100m for business development in 2016, an investment the company hopes to take advantage of if the financial markets continue to be challenging for young biotechs, driving down valuations for assets.
Biogen reported data from the 6mg/kg cohort of its PRIME trial of aducanumab at the Alzheimer's Association International Conference (AAIC) on 22 July that will likely leave investors itching for more clarity. The data continue to show dose correlation in efficacy, but safety issues persist at the mid-range dose as well.